Saturday, March 25, 2023

Covaxin

NTAGI to review Covaxin and Corbevax data for 6-12 years today

Government advisory panel NTAGI will meet on Thursday to review data on Covaxin and Corbevax vaccines for the 6-12 age group and also deliberate on reducing the gap between the second and precaution doses from the current nine to...

‘No impact of WHO action on Covaxin, have not supplied to any UN agency’

With WHO announcing the suspension of Covaxin supply through UN procurement agencies, Bharat Biotech sources said on Monday the pharma company has not supplied the COVID-19 vaccine to any UN agency and no impact of the suspension would be...

Rise in antibodies post Covaxin booster dose: MoS

An ICMR study to examine the effect of Covaxin’s booster dose has shown an increase in the levels of antibodies against SARS-CoV-2, Minister of State for Health Bharati Pravin Pawar told the Rajya Sabha on Tuesday.International data available on...

Covishield, Covaxin likely to be capped at Rs 275 after approval

The price of Covishield and Covaxin, the Covid vaccines which are expected to soon get regular market approval from India’s drug regulator, is likely to be capped at Rs 275 per dose plus an additional service charge of Rs...

Vax for 12-14 age group likely by March

India may begin inoculating children in the 12-14 age group against Covid-19 in March as the 15-18 population is likely to get fully vaccinated by then, Dr N K Arora, chairman of the Covid-19 working group of NTAGI, said...

‘Cannot cut corners’ in approving Covaxin: WHO

The World Health Organisation said on Monday that it is expecting one additional piece of information from Bharat Biotech regarding its COVID-19 vaccine ‘COVAXIN’ and emphasised that it has to thoroughly evaluate to ensure vaccines are safe and “cannot...